Federated Hermes’s Alaunos Therapeutics TCRT Stock Holding History

Federated Hermes’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20	Closed	-$2K	–	2274
2022 Q1	$2K	Buy	+20	New	+$2.57K	﹤0.01%	2037
2019 Q4	–	Sell	-1,666	Closed	-$1.07M	–	2304
2019 Q3	$1.07M	Buy	1,666 +1,568	+1,600%	+$1.24M	﹤0.01%	1256
2019 Q2	$85K	Buy	+98	New	+$67.4K	﹤0.01%	1629
2016 Q1	–	Sell	-42	Closed	-$52K	–	2171
2015 Q4	$52K	Buy	+42	New	+$69.5K	﹤0.01%	1684
2015 Q3	–	Sell	-1	Closed	-$1K	–	2040
2015 Q2	$1K	Buy	+1	New	+$1.55K	﹤0.01%	1911

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Federated Hermes's TCRT Position: Q2 2022 in Review

Federated Hermes sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 20 shares — an estimated $2K sold.

Federated Hermes first reported a position in TCRT in Q2 2015 and held it in 5 quarters. The position peaked at $1.07M in Q3 2019. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

Federated Hermes reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
Federated Hermes sold 20 Alaunos Therapeutics shares in Q2 2022, an estimated $2K.
Federated Hermes first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 5 quarters.
Federated Hermes's Alaunos Therapeutics position peaked at $1.07M in Q3 2019.
124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Federated Hermes's 13F filing for Q2 2022, filed 15 Aug 2022.